Barner Goes Out On A High As Boehringer Ingelheim Returns To Growth

Professor Dr Andreas Barner, the outgoing chief of Boehringer Ingelheim, was able to report a return to growth for the family-owned German company in 2015 at his final annual conference. The group was boosted by diabetes sales under its partnership with Eli Lilly & Co - as well as by the strength of the dollar. The company reports in euros but books nearly 40% of its sales in the US. With currency effects stripped out, the sales were up by a more modest 4.1% versus the 11.1% as reported.

chart

Professor Dr Andreas Barner, the outgoing chief of Boehringer Ingelheim, was able to report a return to growth for the family-owned German company in 2015 at his final annual conference. The group was boosted by diabetes sales under its partnership with Eli Lilly & Co - as well as by the strength of the dollar. The company reports in euros but books nearly 40% of its sales in the US. With currency effects stripped out, the sales were up by a more modest 4.1% versus the 11.1% as reported.

The company's anticoagulant Pradaxa (dabigatran) is still failing to meet previous expectations, though. Barner was bullish about its prospects, citing the US and European approval in the second half of 2015 of the reversal agent Praxbind (idarucizumab), and the fact that 30-35% of atrial fibrillation patients are still not on an anticoagulant, as likely drivers of demand this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By 

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

More from Therapy Areas